Subscribe To Our Free Newsletter |
Sun Pharma Q3 Results: PAT jumps 5.2% to Rs 2166 crore
The earnings before interest, tax, depreciation and ammortisation (EBITDA) grew 15.2% YoY to Rs. 3004 crore. The EBITDA margin for Q3FY23 improved 30 basis points YoY to 26.7%.Global specialty drug sales were at $235 million, including US$12.5 million milestone received in Q3FY23. Ex-milestone, the specialty sales were up 21.6% YoY in Q3FY23.